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Abstract
The objective of this prospective cohort study was to determine whether admission to an intensive care unit (ICU) room previously
occupied by a patient with multidrug-resistant (MDR) Gram-negative bacilli (GNB) increases the risk of acquiring these bacteria by sub-
sequent patients. All patients hospitalized for >48 h were eligible. Patients with MDR GNB at ICU admission were excluded. The MDR
GNB were deﬁned as MDR Pseudomonas aeruginosa, Acinetobacter baumannii and extended spectrum b-lactamase (ESBL) -producing
GNB. All patients were hospitalized in single rooms. Cleaning of ICU rooms between two patients was performed using quaternary
ammonium disinfectant. Risk factors for MDR P. aeruginosa, A. baumannii and ESBL-producing GNB were determined using univariate
and multivariate analysis. Five hundred and eleven consecutive patients were included; ICU-acquired MDR P. aeruginosa was diagnosed
in 82 (16%) patients, A. baumannii in 57 (11%) patients, and ESBL-producing GNB in 50 (9%) patients. Independent risk factors for ICU-
acquired MDR P. aeruginosa were prior occupant with MDR P. aeruginosa (OR 2.3, 95% CI 1.2–4.3, p 0.012), surgery (OR 1.9, 95% CI
1.1–3.6, p 0.024), and prior piperacillin/tazobactam use (OR 1.2, 95% CI 1.1–1.3, p 0.040). Independent risk factors for ICU-acquired
A. baumannii were prior occupant with A. baumannii (OR 4.2, 95% CI 2–8.8, p <0.001), and mechanical ventilation (OR 9.3, 95% CI 1.1–
83, p 0.045). Independent risk factors for ICU-acquired ESBL-producing GNB were tracheostomy (OR 2.6, 95% CI 1.1–6.5, p 0.049),
and sedation (OR 6.6, 95% CI 1.1–40, p 0.041). We conclude that admission to an ICU room previously occupied by a patient with
MDR P. aeruginosa or A. baumannii is an independent risk factor for acquisition of these bacteria by subsequent room occupants. This
relationship was not identiﬁed for ESBL-producing GNB.
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Multidrug resistant (MDR) bacteria are common among
intensive care unit (ICU) patients. According to the results
of a recent large international study performed in 1265 ICUs
[1], infection was present in 51% of the 13 796 included
patients. Infection was microbiologically conﬁrmed in 69.8%
of these patients, and MDR bacteria accounted for 44% of
all bacteria. Patients with ICU-acquired infections related
to MDR bacteria frequently receive inappropriate initial
antibiotic treatment [2,3]. In addition, infections related to
these bacteria are associated with increased morbidity and
mortality [4,5].
Patients in the ICU are commonly exposed to broad-spec-
trum antimicrobial agents, and the ICU presents ample
opportunities for the cross-transmission of MDR bacteria
from patient to patient [6]. Environmental contamination
with MDR bacteria occurs during the care of patients har-
bouring these bacteria [7,8]. Huang et al. [9] performed a
20-month retrospective multicentre study to determine the
risk of acquiring resistant bacteria from prior room occu-
pants. Among patients whose prior room occupant was posi-
tive for methicillin-resistant Staphylococcus aureus (MRSA),
3.9% acquired MRSA compared with 2.9% of patients whose
prior room occupant was MRSA negative (OR 1.4, p 0.04).
Among patients whose prior room occupant was positive for
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vancomycin-resistant enterococci (VRE), these values were
4.5% and 2.8%, respectively (OR 1.4, p 0.02). Another recent
study was performed during a 14-month period [10]. Weekly
environmental cultures, and twice weekly patient surveillance
cultures were performed in two ICUs. The authors found
that prior room contamination, whether measured via envi-
ronmental cultures or prior room occupancy by VRE-colo-
nized patients, was highly predictive of VRE acquisition.
To the best of our knowledge, no study has evaluated the
risk of acquiring MDR Gram-negative bacilli (GNB) from
prior room occupants. However, these bacteria are fre-
quently isolated in critically ill patients [1,11]. In addition,
infections related to these bacteria are difﬁcult to treat with
frequent inappropriate initial antibiotic treatment, and high
mortality and morbidity rates [3]. Therefore, we performed
this prospective observational study to determine the rela-
tionship between colonization or infection with MDR GNB
in prior room occupants and the risk of acquiring these bac-
teria by subsequent patients.
Patients and Methods
Study design
This prospective observational cohort study was conducted
from December 2006 to December 2007. No informed con-
sent was required by the local Institutional Review Board
because of the non-interventional design of the study. Eligibil-
ity criteria included admission to the ICU during the study
period, and length of ICU stay >48 h. Patients with coloniza-
tion or infection related to MDR GNB at ICU admission
were excluded.
Study population
The study was performed in a 30-bed medical and surgical
ICU, including three ten-bed units. All ICU rooms were sin-
gle beds. Healthcare workers did not share patient care
between subunits. In addition, in each subunit the staff mem-
bers were not responsible for speciﬁc ICU rooms. Cleaning
of ICU rooms was performed at patient discharge using qua-
ternary ammonium disinfectant. The infection control policy
included isolation techniques, routine screening of MDR bac-
teria, written antibiotic treatment protocol, and continuous
surveillance of nosocomial infections. In immunocompetent
patients, isolation techniques were used for all patients at
ICU admission, until receipt of screening results. Thereafter,
these techniques were performed for all patients with infec-
tion or colonization related to MDR bacteria. Preventive iso-
lation techniques were applied for all immunosuppressed
patients. These techniques included use of protective gowns
and gloves associated with adequate hand hygiene using alco-
hol-based hand rub formulations before and after patient
contacts.
Routine screening of MDR bacteria was performed for all
patients at ICU admission and weekly thereafter. This
screening included nasal and rectal swabs. In addition, tra-
cheal aspirate was performed in intubated or tracheotomized
patients. Screening of MDR bacteria has been performed in
our ICU as part of the infection control policy, and not for
the purpose of this study. Other microbiological cultures
were performed according to clinical status.
During the study period a quality audit was performed in
50 consecutive patients. Direct observation of healthcare
workers was used by a student to assess compliance with
disinfection protocol at patient discharge. A checklist of
objects to clean was used to determine the percentage of
objects cleaned at ICU discharge.
Data collection and deﬁnitions
All data on patient characteristics at ICU admission, and dur-
ing ICU stay, were prospectively collected. The MDR GNB
were deﬁned as Pseudomonas aeruginosa resistant to ceftazi-
dime or imipenem, Acinetobacter baumannii, and extended
spectrum b-lactamase (ESBL) -producing GNB. The MDR
GNB were deﬁned as ICU-acquired if they were diagnosed
>48 h after admission to ICU. A prior room occupant was
considered as having the same MDR GNB as the next
patient when any screening or diagnostic sample was positive
for an MDR GNB that was subsequently isolated, on screen-
ing or diagnostic samples, in the next patient. Prior antibiotic
treatment was deﬁned as any antibiotic treatment during the
3 months preceding ICU admission. Colonization pressure
was assessed daily, and was deﬁned as the number of
patients with MDR P. aeruginosa, A. baumannii or ESBL-
producing GNB divided by the number of all patients in each
ten-bed unit. McCabe score [12], chronic obstructive pulmo-
nary disease [13] and immunosuppression [14] are deﬁned
elsewhere.
Statistical methods
SPSS 11.5 software (SPSS, Chicago, IL) was used for data
analysis. Results are presented as number (percentage) for
categorical variables. Distribution of quantitative variables
was tested. Median values were 0 for several quantitative
variables, because of their skewed distribution. Therefore, all
quantitative variables are presented as mean ± SD. All p val-
ues were two-tailed. The statistical signiﬁcance was deﬁned
as p <0.05.
Univariate analysis was used to determine factors associ-
ated with ICU-acquired MDR P. aeruginosa, A. baumannii and
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ESBL-producing GNB. Qualitative variables were compared
using the Pearson chi-square test or the Fisher’s exact test,
as appropriate. Quantitative variables were compared using
the Mann–Whitney U-test or the Student’s t-test, as appro-
priate.
Multivariate analysis was used to determine factors inde-
pendently associated with different ICU-acquired MDR
P. aeruginosa, A. baumannii and ESBL-producing GNB. All pre-
dictors showing a p <0.1 association with ICU-acquired
MDR bacteria in univariate analysis were incorporated in the
multivariate logistic regression analysis. Potential interactions
were tested. Clinical judgement was used to select the vari-
able to introduce in the logistic regression model when an
interaction was present between two variables. Odds ratios
and 95% CI were calculated, as well as the Hosmer–Lem-
show goodness-of-ﬁt.
Exposure to risk factors for ICU-acquired MDR GNB was
taken into account until the acquisition of MDR GNB, or
until ICU discharge, in patients with and without ICU-
acquired MDR GNB, respectively.
Results
Five hundred and eleven patients were eligible and were all
included. Infection and colonization related to MDR GNB
were diagnosed in 65 (79%) and 17 (20%) patients with
P. aeruginosa, in 46 (80%) and 11 (19%) patients with A. bau-
mannii, and in 42 (84%) and 8 (6%) patients with ESBL-
producing GNB, respectively.
Patient characteristics are presented in Tables 1–4. Dura-
tion of mechanical ventilation and of ICU stay were signiﬁ-
cantly longer in patients with MDR P. aeruginosa, A. baumannii
or ESBL-producing GNB compared with patients without
these bacteria. Although ICU mortality was signiﬁcantly
higher in patients with MDR P. aeruginosa compared with
patients without MDR P. aeruginosa, ICU mortality was
similar in patients with and without A. baumannii or ESBL-
producing GNB (Tables 2 and 4).
Several risk factors for ICU-acquired MDR P. aeruginosa,
A. baumannii and ESBL-producing GNB were identiﬁed by
univariate analyses, and are presented in Tables 1–4. Inde-
pendent risk factors for ICU-acquired P. aeruginosa were
prior occupant with MDR P. aeruginosa, surgery and prior
use of piperacillin/tazobactam. Independent risk factors for
ICU-acquired A. baumannii were prior occupant with A. bau-
mannii and mechanical ventilation. Independent risk factors
for ICU-acquired ESBL-producing GNB were tracheostomy
and sedation (Table 5).
Time from ICU discharge of prior room occupants with
MDR GNB to acquisition of these bacteria by subsequent
patients was 5 ± 2 days, 6 ± 2 days and 20 ± 16 days in
patients with P. aeruginosa, A. baumannii and ESBL-producing
GNB, respectively. Although this time interval was signiﬁ-
cantly (p <0.001) shorter in patients with P. aeruginosa or
A. baumannii with prior room occupant having the same
MDR GNB compared with those without prior room occu-
pant with the same MDR GNB, no signiﬁcant difference
(p 0.582) was found in this time interval between patients
with ESBL-producing GNB with prior room occupant having
TABLE1. Characteristics of patients with and without multidrug-resistant Pseudomonas aeruginosa (MDRPA) or Acinetobacter
baumannii at intensive-care unit (ICU) admission
ICU-acquired MDRPA
p value OR (95% CI)
ICU-acquired A. baumannii
p value OR (95% CI)Yes (n = 82) No (n = 429) Yes (n = 57) No (n = 454)
Age, years 60 ± 16 55 ± 19 0.040 NA 59 ± 16 56 ± 18 0.175 NA
Male gender 54 (65) 298 (69) 0.518 0.8 (0.5–1.3) 37 (68) 315 (69) 0.544 0.8 (0.4–1.4)
SAPS II 52 ± 19 44 ± 20 <0.001 NA 53 ± 18 44 ± 20 0.002 NA
LOD score 6.3 ± 3.7 5.2 ± 3.4 0.002 NA 6.4 ± 3.7 5.3 ± 3.4 <0.001 NA
Ultimately or rapidly fatal diseasea 49 (59) 213 (49) 0.117 1.5 (.9–2.4) 34 (59) 228 (50) 0.206 1.4 (0.8–2.5)
Transfer from other wards 65 (79) 240 (55) <0.001 3 (1.7–5.3) 39 (68) 266 (58) 0.197 1.5 (0.8–2.7)
Duration of hospitalization before
ICU admission, days
7 ± 11 5 ± 9 <0.001 NA 5 ± 7 5 ± 10 0.137 NA
Category of admission
Medical 44 (53) 330 (76) <0.001 2.9 (1.8–4.7) 36 (63) 338 (74) 0.081 1.7 (0.9–3)
Surgical 38 (46) 99 (23) 21 (36) 116 (25)
Comorbidities
Diabetes mellitus 16 (19) 83 (19) >0.999 1.01 (0.5–1.8) 12 (21) 87 (19) 0.724 1.1 (0.5–2.2)
COPD 21 (25) 116 (27) 0.892 0.9 (0.5–1.5) 11 (19) 126 (27) 0.206 0.6 (0.3–1.2)
Liver cirrhosis 1 (1) 14 (3) 0.484 0.3 (0.1–2.8) 4 (7) 11 (2) 0.074 3 (0.9–9.8)
Chronic dialysis 1 (1) 13 (3) 0.709 0.3 (0.1–3) 1 (1) 13 (2) >0.999 0.6 (0.1–4.7)
Immunosuppression 20 (24) 88 (20) 0.461 1.2 (0.7–2.1) 16 (28) 92 (20) 0.172 1.5 (0.8–2.8)
Prior antimicrobial treatment 46 (56) 163 (38) 0.003 2.1 (1.3–3.4) 30 (52) 179 (39) 0.064 1.7 (0.9–2.9)
Data are N (%) or mean ± SD. Results by univariate analysis. OR (95% CI) were only calculated for qualitative variables.
NA, not applicable; SAPS, simpliﬁed acute physiology score, LOD, logistic organ dysfunction; COPD, chronic obstructive pulmonary disease.
aAccording to McCabe score (Ref).
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the same bacterium compared with those without prior
room occupant with ESBL-producing GNB (Fig. 1).
The quality audit performed during the study on 50 con-
secutive patients demonstrated that 56% of objects were
correctly cleaned after ICU discharge. The most frequently
incorrectly cleaned objects included room door knobs
(45%), monitor screens (27%) and bedside tables (16%).
To determine the impact of colonization compared with
infection on acquisition of MDR GNB by the next room
occupant, we repeated all univariate and multivariate analyses
in the subgroups of patients with colonization and infection.
Similar results were found suggesting that the risk of acquir-
ing MDR GNB did not differ according to the presence of
colonization compared with infection in the prior room
occupant (data not shown).
Discussion
The main results of our study are that admission to an ICU
room previously occupied by a carrier of MDR P. aeruginosa
or A. baumannii is an independent risk factor for acquisition
of these bacteria by subsequent room occupants. However,
this relationship was not identiﬁed for ESBL-producing GNB.
To the best of our knowledge, our study is the ﬁrst to
identify prior room occupant with MDR P. aeruginosa or
A. baumannii as an independent risk factor for subsequent
room occupants to acquire these bacteria. Previous studies
found similar results with regard to MRSA, VRE and Clos-
tridium difﬁcile [9,10,15,16]. Our results suggest that the
contamination of ICU rooms (e.g. surfaces and equipment)
plays an important role in the spread of MDR P. aeruginosa
and A. baumannii. Several studies have documented the
contamination of sinks and sink drains by P. aeruginosa
[17–19]. Other studies demonstrated that A. baumannii was
isolated throughout the inanimate environment, on the
beds of colonized patients and on nearby surfaces (e.g. on
mattresses and bedside equipment), in hospital rooms (e.g.
on ﬂoors, sinks, countertops and door handles), and in
room humidiﬁers [7,20,21]. In addition, it has been demon-
strated that MRSA, VRE and A. baumannii are readily trans-
mitted from environmental surfaces to healthcare workers’
hands [22–24]. However, many of these studies were per-
formed in an outbreak setting [25]. In addition, few studies
TABLE 2. Characteristics of patients with or without multidrug-resistant (MDR) Pseudomonas aeruginosa or Acinetobacter
baumannii during intensive-care unit (ICU) stay
ICU-acquired MDRPA
p value OR (95% CI)
ICU-acquired A. baumannii
p value OR (95% CI)Yes (n = 82) No (n = 429) Yes (n = 57) No (n = 454)
Prior room occupants with the same
MDR GNB
21 (25) 64 (14) 0.023 1.9 (1.1–3.5) 16 (28) 36 (7) <0.001 4.5 (2.3–8.9)
Colonization pressure, % 45 ± 15 43 ± 15 0.298 NA 51 ± 15 43 ± 14 0.003 NA
Room occupancy rate, % 97 ± 4 95 ± 5 0.041 NA 96 ± 6 95 ± 5 0.183 NA
Central venous catheter 78 (95) 323 (75) <0.001 6.3 (2.3–17.9) 54 (94) 347 (76) 0.001 5.5 (1.7–18)
Arterial catheter 77 (93) 295 (68) <0.001 6.9 (2.8–17.7) 53 (93) 319 (70) <0.001 5.6 (1.9–15.9)
Urinary catheter 79 (96) 359 (83) 0.002 5.1 (1.6–16.7) 55 (96) 383 (84) 0.009 5.1 (1.2–21)
Tracheostomy 17 (20) 42 (9) 0.008 2.4 (1.3–4.5) 9 (15) 50 (11) 0.257 1.5 (0.7–3.2)
Sedation 74 (90) 289 (67) <0.001 4.5 (2.1–9.6) 51 (89) 312 (68) 0.001 3.9 (1.6–9.2)
Antimicrobial treatment 78 (95) 352 (82) 0.002 4.2 (1.5–12) 55 (96) 374 (82) 0.004 5.9 (1.4–24.6)
Duration of antimicrobial treatment 15 ± 9 12 ± 10 0.002 NA 13 ± 9 15 ± 13 0.881 NA
Percentage of days in the ICU with
antimicrobials
74 ± 32 65 ± 36 0.035 NA 68 ± 34 66 ± 35 0.674 NA
Penicillins 1 ± 6 3 ± 12 0.265 NA 4 ± 18 3 ± 12 0.886 NA
Amoxicillin-clavulanate acid 12 ± 26 22 ± 34 0.012 NA 16 ± 31 21 ± 34 0.227 NA
Piperacillin-tazobactam 41 ± 41 21 ± 34 <0.001 NA 39 ± 41 21 ± 34 <0.001 NA
Third-generation cephalosporins 8 ± 20 9 ± 23 0.690 NA 12 ± 26 9 ± 22 0.300 NA
Fourth-generation cephalosporins 3 ± 8 3 ± 13 0.067 NA 1 ± 7 4 ± 14 0.035 NA
Carbapenems 10 ± 22 5 ± 17 0.013 NA 5 ± 14 7 ± 19 0.495 NA
Fluoroquinolones 23 ± 32 17 ± 31 0.062 NA 29 ± 36 17 ± 30 0.012 NA
Aminoglycosides 18 ± 27 11 ± 23 0.001 NA 10 ± 19 13 ± 24 0.865 NA
Mechanical ventilation 76 (92) 327 (76) 0.001 3.9 (1.7–9.3) 56 (98) 346 (76) <0.001 17.3 (2.6–126)
Duration of mechanical ventilation
before MDRPA/A. baumannii acquisition
or extubation, daysa
19 ± 10 13 ± 11 <0.001 NA 16 ± 13 16 ± 15 0.290 NA
Total duration of mechanical ventilation,
days
36 ± 23 13 ± 11 <0.001 NA 29 ± 22 16 ± 15 <0.001 NA
Length of stay before ICU-acquired
MDRPA/A. baumannii or ICU discharge,
daysa
21 ± 15 15 ± 13 <0.001 NA 17 ± 14 18 ± 17 0.682 NA
Total duration of ICU stay, days 41 ± 27 15 ± 13 <0.001 NA 34 ± 24 18 ± 17 <0.001 NA
ICU-mortality 39 (47) 133 (31) 0.005 2 (1.2–3.2) 23 (40) (32) 0.298 1.3 (0.7–2.4)
Data are N (%) or mean ± SD. Results by univariate analysis. OR (95% CI) were only calculated for qualitative variables.
Exposure to risk factors was taken into account until MDRPA, or A. baumannii occurrence, and until ICU discharge in patients with and without these bacteria; respectively.
aIn patients with MDRPA/A. baumannii, and patients without these bacteria; respectively.
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used molecular epidemiology (e.g. pulsed-ﬁeld gel electro-
phoresis) [26].
One important limitation of our study is that environmen-
tal cultures were not performed to conﬁrm the role of envi-
ronmental contamination in MDR GNB transmission from
prior room occupant to subsequent patient. However, the
shorter time interval from ICU discharge to P. aeruginosa or
A. baumannii acquisition in patients with prior room occupant
having the same MDR GNB compared with those for whom
the prior room occupant did not have the same MDR GNB
indicates that environmental contamination is plausible.
Another potential explanation of the ﬁndings is that the
room itself did not transmit the pathogens, but that certain
rooms were associated with speciﬁc staff members and that
the staff members transmitted the organism from one patient
to another. However, staff members were not responsible
for speciﬁc ICU rooms. Molecular typing of all strains could
have proved the similarity of MDR GNB strains between
prior room occupant and subsequent patient. Unfortunately,
molecular typing of all MDR GNB strains was not possible
during the study period. In addition, this study was per-
formed in a single centre so the results may not be general-
izable to other centres.
Duration of survival of non-fermenting GNB has been
reported to be as long as 48 h for P. aeruginosa on dry
TABLE 4. Characteristics of pati-
ents with or without intensive-care
unit (ICU) -acquired extended
spectrum b-lactamase (ESBL) -pro-
ducing Gram-negative bacteria
(GNB) during ICU stay
ICU-acquired
ESBL-producing GNB
p value OR (95% CI)Yes (n = 50) No (n = 461)
Prior room occupants with ESBL-producing GNB 8 (16) 50 (10) 0.249 1.5 (0.6–3.5)
Colonization pressure 49 ± 11 43 ± 15 0.021 NA
Room occupancy rate 0.95 ± 0.05 0.95 ± 0.06 0.600 NA
Central venous catheter 49 (98) 352 (76) <0.001 15.2 (2.1–111)
Arterial catheter 48 (96) 324 (70) <0.001 10 (2.4–42.3)
Urinary catheter 50 (100) 388 (84) <0.001 1.1 (1.1–1.2)
Tracheostomy 11 (22) 48 (10) 0.032 2.4 (1.2–5.1)
Sedation 48 (96) 315 (68) <0.001 11.1 (2.7–46.4)
Antimicrobial treatment 49 (98) 383 (83) 0.003 9.9 (1.4–73.4)
Duration of antimicrobial treatment, days 20 ± 15 15 ± 12 0.005 NA
Percentage of days in the ICU with antimicrobials 75 ± 31 65 ± 36 0.066 NA
Penicillins 3 ± 12 3 ± 13 0.492 NA
Amoxicillin-clavulanate acid 21 ± 36 21 ± 33 0.298 NA
Piperacillin-tazobactam 31 ± 39 21 ± 34 0.030 NA
Third-generation cephalosporins 10 ± 24 8 ± 22 0.245 NA
Fourth-generation cephalosporins 6 ± 13 3 ± 13 0.001 NA
Carbapenems 15 ± 27 6 ± 17 0.027 NA
Fluoroquinolones 24 ± 30 18 ± 31 0.011 NA
Aminoglycosides 15 ± 23 12 ± 23 0.180 NA
Mechanical ventilation 47 (94) 355 (77) 0.003 4.7 (1.4–15.3)
Duration of mechanical ventilation before
ESBL-producing GNB acquisition or extubation, daysa
20 ± 14 16 ± 14 0.002 NA
Total duration of mechanical ventilation, days 28 ± 18 16 ± 15 <0.001 NA
Length of ICU stay before ESBL-producing
GNB acquisition or ICU discharge, daysa
23 ± 21 18 ± 17 0.060 NA
Total length of ICU stay, days 36 ± 26 18 ± 17 <0.001 NA
ICU-mortality 19 (38) 153 (33) 0.530 1.2 (0.6–2.2)
Data are N (%) or mean ± SD. Results by univariate analysis. OR (95% CI) were calculated for only qualitative vari-
ables.
GNB, Gram-negative bacilli; ICU, intensive care unit; NA, not applicable.
Exposure to risk factors was taken into account until ESBL-producing GNB acquisition, or until ICU discharge, in
patients with and without ESBL-producing GNB; respectively.
aIn patients with and without ESBL-producing GNB, respectively.
TABLE 3. Characteristics of patients with or without inten-
sive0care unit (ICU) -acquired extended spectrum b-lactam-




p value OR (95% CI)Yes (n = 50) No (n = 461)
Age 60 ± 12 56 ± 19 0.178 NA
Male gender 32 (64) 320 (69) 0.426 0.7 (0.4–1.4)
SAPS II 51 ± 21 45 ± 20 0.047 NA
LOD score 5.5 ± 3.6 5.4 ± 3.5 0.080 NA
Ultimately or rapidly
fatal diseasea
28 (56) 234 (50) 0.552 1.2 (0.6–2.2)
Transfer from other
wards





4 ± 6 5 ± 10 0.176 NA
Category of admission
Medical 36 (72) 338 (73) 0.876 1.1 (0.5–2)
Surgical 14 (28) 123 (26)
Comorbidities
Diabetes mellitus 10 (20) 89 (19) 0.852 1.1 (0.7–2.7)
COPD 17 (34) 120 (26) 0.241 1.4 (0.7–2.7)
Liver cirrhosis 2 (4) 13 (2) 0.650 1.4 (0.3–6.5)
Chronic dialysis 0 14 (3) 0.381 NA
Immunosuppression 12 (24) 96 (20) 0.587 1.2 (0.6–2.3)
Prior antimicrobial
treatment
26 (52) 183 (39) 0.098 1.6 (0.9–2.9)
Data are N (%) or mean ± SD. Results by univariate analysis. OR (95% CI)
were only calculated for qualitative variables.
NA, not applicable; SAPS, simpliﬁed acute physiology score, LOD, logistic organ
dysfunction; COPD, chronic obstructive pulmonary disease.
aAccording to McCabe score (Ref 12).
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surfaces [27], and up to 33 days for A. baumannii on plastic
laminate surfaces [28]. The absence of a relationship
between colonization of prior room occupant with ESBL-
producing GNB and acquisition of this GNB by the subse-
quent room occupant could be explained by the fact that
survival of ESBL-producing GNB on inanimate surfaces is
probably shorter compared with survival of P. aeruginosa and
A. baumannii [29].
Cleaning of our ICU rooms was probably not efﬁcient in
eradicating MDR P. aeruginosa and A. baumannii. Two poten-
tial explanations could be provided. First, compliance with
cleaning protocol was not optimal, as suggested by the qual-
ity audit performed during the study period. A recent multi-
centre study evaluated the thoroughness of terminal cleaning
in 260 ICU rooms using a ﬂuorescent targeting method [30].
Only 49.5% of surfaces were correctly cleaned. After inter-
vention and multiple cycles of objective performance
feedback to environmental services staff, thoroughness of
cleaning improved to 82%. Second, our cleaning technique,
using quaternary ammonium disinfectant, may not be efﬁcient
in eradicating MDR P. aeruginosa and A. baumannii [8]. New
methods have recently been reported to improve cleaning of
hospital rooms. A hydrogen peroxide dry-mist disinfection
system was found to be signiﬁcantly more effective than 0.5%
sodium hypochlorite solution in eradicating C. difﬁcile spores
[31]. Hydrogen peroxide vapour decontamination also effec-
tively eradicated important healthcare-associated pathogens
such as MRSA, VRE, A. baumannii, Serratia, mycobacteria and
viruses [32–35]. However, limitations of these studies
included retrospective, observational or before–after designs,
and the small number of patients included. In addition, the
quality of the disinfecting process was not controlled during
these studies. A recent study demonstrated that the novel
automated ultraviolet radiation device signiﬁcantly reduces
C. difﬁcile, VRE and MRSA contamination on commonly
touched hospital surfaces [36]. Although innovative technolo-
gies may play a role in the environmental hygiene armamen-
tarium, their logistical complexity, as well as the equipment
and personnel costs of these interventions, makes it impera-
tive that independent or consortium-sponsored, objectively



















FIG. 1. Mean time from prior room occupant discharge to acquisi-
tion of multidrug-resistant Gram-negative bacteria (MDR GNB) in
subsequent patients with and without prior room occupant having
the same MDR GNB. Grey bars represent patients with prior room
occupant having the same MDR GNB, black bars represent patients
for whom prior room occupant did not have the same MDR GNB.
MDRPA, MDR Pseudomonas aeruginosa; AB, Acinetobacter baumannii;
ESBL, extended spectrum b-lactamase-producing GNB. p <0.001 for
patients with P. aeruginosa or A. baumanni with prior room occupant
having the same MDR GNB compared with patients without prior
room occupant with the same MDR GNB, p 0.582 for patients with
ESBL-producing GNB and prior room occupant with ESBL-producing
GNB compared with those without prior room occupant with ESBL-
producing GNB.
TABLE 5. Independent risk factors for intensive care unit
(ICU) -acquired multidrug-resistant (MDR) Pseudomonas
aeruginosa, Acinetobacter baumannii, and extended spectrum
b-lactamase (ESBL) -producing Gram-negative bacteria
(GNB)
Risk factors OR (95% CI) p value
MDR P. aeruginosa
Prior occupant with MDR P. aeruginosa 2.3 (1.2–4.3) 0.012
Surgery 1.9 (1.1–3.6) 0.024
Prior piperacillin/tazobactam use 1.2 (1.1–1.3) 0.040
A. baumannii
Prior occupant with A. baumannii 4.2 (2–8.8) <0.001
Mechanical ventilation 9.3 (1.1–83) 0.045
ESBL-producing GNB
Tracheostomy 2.6 (1.1–6.5) 0.049
Sedation 6.6 (1.1–40) 0.041
Results by multivariate analysis. Hosmer–Lemeshow goodness-of-ﬁt test,
p 0.588, p 0.941, p 0.329 for MDR P. aeruginosa, A. baumannii, and ESBL; respec-
tively. Model signiﬁcance <0.005 for all multivariate analyses.
The following variables were not signiﬁcant in the ﬁnal model of risk factors for
ICU-acquired MDR P. aeruginosa: age, simpliﬁed acute physiology score (SAPS
II), logistic organ dysfunction (LOD) score, transfer from other wards, duration
of hospitalization before ICU admission, prior antibiotic treatment, room occu-
pancy rate, central venous catheter, arterial catheter, urinary catheter, tracheos-
tomy, sedation, percentage of days in the ICU with amoxicillin-clavulanate acid,
percentage of days in the ICU with piperacillin-tazobactam, percentage of days
in the ICU with fourth-generation cephalosporins, percentage of days in the
ICU with carbapenems, percentage of days in the ICU with ﬂuoroquinolones,
percentage of days in the ICU with aminoglycosides, mechanical ventilation, and
length of ICU stay.
The following variables were not signiﬁcant in the ﬁnal model of risk factors for
ICU-acquired A. baumannii: SAPS II, LOD, category of admission, prior antibiotic
treatment, colonization pressure, central venous catheter, arterial catheter, uri-
nary catheter, sedation, percentage of days in the ICU with piperacillin-tazobac-
tam, percentage of days in the ICU with fourth-generation cephalosporins,
percentage of days in the ICU with ﬂuoroquinolones.
The following variables were not signiﬁcant in the ﬁnal model of risk factors for
ICU-acquired ESBL-producing GNB: SAPS II, LOD, prior antibiotic treatment,
colonization pressure, central venous catheter, arterial catheter, urinary cathe-
ter, percentage of days in the ICU with piperacillin-tazobactam, percentage of
days in the ICU with fourth-generation cephalosporins, percentage of days in
the ICU with carbapenems, percentage of days in the ICU with ﬂuoroquinol-
ones, mechanical ventilation, length of ICU stay
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Surgery and prior use of piperacillin/tazobactam were
identiﬁed as independent risk factors for ICU-acquired
MDR P. aeruginosa. Use of mechanical ventilation was
identiﬁed as an independent risk factor for ICU-acquired
A. baumannii. Tracheostomy and sedation were identiﬁed
as independent risk factors for ICU-acquired ESBL-produc-
ing GNB. These results are in line with previous ﬁndings
[38–45].
We conclude that admission to an ICU room previously
occupied by a carrier of MDR P. aeruginosa or A. baumannii is
an independent risk factor for the acquiring of these bacteria
by subsequent room occupants. However, this relationship
was not identiﬁed for ESBL-producing GNB. Future studies
should determine the efﬁciency of new cleaning and disinfec-
tion methods on transmission of MDR GNB in critically ill
patients.
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